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and valvular heart disease. However, there have been few studies on the risk
for development of AF in an elderly cohort, taking into account ECG vari-
ables.
Aims: We aimed to evaluate the clinical and ECG predictors of preva-
lent AF in a large population-based prospective cohort study. The clinical
and ECG workups were realized at admission and after 4 years of follow-
up.
Methods: The study is part of the Three City Study (COVADIS), which
included subjects aged 65 years and above and not institutionalised. The prev-
alence of AF at baseline was assessed in 4234 patients.
Results: The overall prevalence was 2,33%. Based on multivariable
analyses, the HR was 2.08 [95% CI: 1.07-4.54], p=0.03) for male gender.
Age above 75 years was associated with an increase of AF prevalence (HR
1.92 [95% CI: 1.24-2.97], p=0.003) as well as history of stroke (HR=2.90
[95% CI: 1.15-6.56], p=0.02), history of AF (HR, 2.74 [95% CI: 1.12-
6.20], p=0.02). None of the other classical clinical risk factors was associ-
ated with AF prevalence. Q waves and ST segment depression on the base-
line ECG were associated with an increased prevalence of AF: HR, 2.70
[95% CI: 2.13-6.44], p<0.001) and HR, 12.6 [95% CI: 6.56-23.8],
p<0.001, respectively.
Conclusion: In a contemporary cohort of elderly subjects, ECG variables
suggesting CAD, history of previous AF, history of stroke, age and gender
were predictors of AF prevalence.
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Purpose: The prevalence of atrial fibrillation (AF) is increasing world-
wide, affecting 4.5 million people in the European Union, and up to 1 million
people in France. Yet, cardioversion practices (CV) are not well documented.
The RHYTHM-AF international observational study aimed to describe
regional patient populations and CV practices.
Methods: Consecutive adult candidates for CV with documented recent
AF were enrolled from hospitals in 10 countries. Information on French
patients was collected between September 2010 and April 2011 in 25 centers.
Descriptive statistics were used to document patient characteristics and CV
practices.
Results: Among the first 492 French enrolled patients, mean age was
69 years, 65% were male, 57% were hypertensive, 16% diabetic and 16%
presented with a history of chronic heart failure while a quarter (26%) showed
heart failure symptoms. Transthoracic and transesophageal echocardiography
were available in 70% and 30% of patients, respectively.
Over half (56%) of all patients underwent an attempt at CV; and the
majority of them (80%) underwent electrical CV. The remaining 20% under-
went pharmacological CV, most (81%) using amiodarone IV. At hospital dis-
charge, the median length of stay was 46 hours (IQR: 26-84) for electrical CV
and 203 hours (IQR: 91-409) for pharmacological CV. Also at discharge, 73%
of patients were in normal sinus rhythm, 92% were prescribed anticoagulation
drugs, and 63% anti-arrhythmic drugs. Adverse events occurred in 3% of
patients and in-hospital mortality was 0.6%.
Conclusions: In France, observations suggest that current cardiology
ward management of recent onset AF involves attempted CV in just over
half of patients considered for CV. Among those cardioverted, treatment is
oriented towards electrical CV, with a median length of in-hospital stay of
2 days. While electrical CV seems to be the preferred option of French
cardiologists, amiodarone IV is nonetheless their first pharmacological
treatment choice.
Table – Results
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Background: Both rate- and rhythm-control are accepted management
strategies for atrial fibrillation (AF). The frequency of success of either
strategy and the impact of control on symptomatic status of AF patients have
not been described,
Methods: RealiseAF was a multicentre, international, observational, cross-
sectional survey of patients with any AF history in the previous 12 months,
performed in 2009-10 by random sampling of cardiologists and internists. It
aimed to describe the characteristics, symptoms, quality of life (QoL), and
management patterns of AF patients, and determine the frequency of AF con-
trol (defined as sinus rhythm or AF with resting heart rate 80 beats per
minute [bpm]).
Findings Of 10546 patients enrolled, 10 523 were eligible for analysis and
9665 evaluable for AF control. AF was controlled in 59.0% of patients (sinus
rhythm 26.5%, AF 80 bpm 32.5%), and uncontrolled in 41.0%. Symptom
prevalence in the previous 7 days was lower in controlled than uncontrolled
AF (55.7% vs 68·4% respectively; p<0.001) and similar for patients in sinus
rhythm and patients in AF 80 bpm (54·8% vs 56.4%; p=0.23). On the day of
the visit, AF-related functional impairment (European Heart Rhythm Associa-
tion Class >1) was observed in 67.4% of controlled and 82.1% of uncontrolled
AF patients (p<0.001). QoL (measured using the EQ-5D tool) was better for
patients with controlled versus uncontrolled AF for all measures: visual analog
Total Cardioverted No CV
Total (N (%)) 492 
(100%)
277 (56%) 215 
(44%)
1st detected AF 169 
(36%)
92 (33%) 77 
(40%)
Paroxsymal AF 94 
(20%)
39 (14%) 55 
(28%)
Persistent AF 144 
(31%)
97 (35%) 47 
(24%)
CHADS2 score (mean, (SD)) 1.3 
(1.1)
1.4 (1.1) 1.1 
(1.0)
Mode of Cardioversion
Total PhCV ECV No CV
Total (N (%)) 492 
(100%)
55 
(11%)
226 
(46%)
215 
(44%)
LoS, hours (median (IQR)) 48 
(22-144)
203 
(91-409)
46
 (26-84)
62 
(4-134)
Time to CV, hours (median 
(IQR))
21 
(16-49)
24 
(5-74)
21
 (18-46)
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scale (mean [standard deviation] score 67.1 [18.4] vs 63.2 [18.9]; p<0.001),
single index utility score (median 0·78 vs 0·73; p<0.001), or the five dimen-
sions of well-being (p<0.001 for each). Irrespective of AF control, cardiovas-
cular events leading to hospitalization had occurred in 28.1% of patients.
Interpretation AF control is not optimal. AF Patients experience frequent
symptoms, functional impairment, altered QoL, and cardiovascular events,
even when AF is controlled. This highlights the need for improved treatment
of AF.
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Tachycardiomyopathy is a rare and treatable cause of heart failure. The
purpose of the study was to determine the prevalence and the factors of atrial
flutter (AFl) – related tachycardiomyopathy.
Methods: 859 patients aged from 18 to 93 years (64±11) were consecu-
tively referred for radiofrequency ablation of AFL between January 1995 and
March 2010. Patients admitted with heart failure and low left ventricular ejec-
tion fraction (LVEF) (<40%) were collected. Patients with normalisation of
LVEF 6 months after AFl ablation and considered as having an AFl-related
tachycardiomyopathy were studied.
Results: AFl-related tachycardiomyopathy was noted in 46 patients (group I);
its prevalence was 5%. 812 patients had no AFl-related tachycardiomyopathy
(group II). Group I (62±12 years) tended to be younger than group II
(64±11.5) (p<0.06). Male gender tended (p 0.06) to be more frequent in group
I (89%) than in group II (73%). Heart disease (HD) was present in 5 group I
patients (11%) (hypertension (HT) 3, valvular HD 1, respiratory failure with
right ventricular (RV) involvement 1) and in 460 group II patients (57%) (val-
vular HD 86, ischemic HD 112, HT and metabolic syndrome 98, respiratory
failure with RV involvement 64, previous dilated cardiomyopathy 38, various
HD’s 30, congenital HD 32). The differences were highly significant
(<0.00001). The prevalence of AFl with 1:1 AV conduction related to a good
AV conduction did not differ significantly in group I (9%) and II (6%). AFl
duration was unknown because the date of beginning cannot be determined
especially in group I patients.
Conclusions: The prevalence of atrial flutter-related tachycardiomyopathy
was low (5%) in a population admitted for atrial flutter. The prevention seems
difficult, because patients prone to Afl-tachycardiomyopathy are relatively
young men without known heart disease and without the feeling of tachy-
cardia.
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Introduction: Gain-of-function mutations in genes coding for potassium
channels were reported in familial atrial fibrillation (AFib). Similar mutations
were also described in families with short QT syndrome (SQT), an entity often
associated to AFib.
Aims: We hypothetized that lone AFib is a minor form of SQT. We sought
to compare the QT intervals of patients with lone atrial fibrillation to QT inter-
vals of an aged and sex matched normal population.
Methods: Heart rate, QT end and QT apex were measured during sinus
rhythm in each of the 12 ECG leads in 66 untreated patients with paroxysmal
lone AFib and in 122 apparied control subjects. Tp-Te was calculated by the
difference between QT end and QT apex.
Results: Mean age was 49±13 yo, 72% were men. Basal resting cardiac
rate was slower in patients with lone AFib than in controls (64±10 vs
69±9 bpm, p=0,0006). Corrected QT end intervals were found shorter in most
ECG leads in patients with lone AFib than in controls (significant for 7/12
ECG leads and borderline in 2 other leads) (mean QTc 381±21 vs 388±22 ms,
p=0,02). There was no significant differences in corrected QT apex, while cor-
rected Tp-Te were significantly shorter in AFib patients in most ECG leads
(mean corrected Tp-Te 67±9 vs 77±10 ms, p<0,0001).
Conclusion: QT interval is significantly shorter and heart rate slower in
patients with idiopathic atrial fibrillation compared to the normal population.
This could be the marker of genetic mutations of cardiac ionic currents pre-
disposing to atrial fibrillation.
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We examined the efficacy and safety of pulmonary vein (PV) isolation
with cryoballoon.
Methods: We studied 259 patients with paroxysmal (n=207) or persistent
(n=52) atrial fibrillation (AF), who underwent isolation of 994 PV with a cry-
oballoon. They were followed every 3 months with a 48-h Holter. We ana-
lyzed the immediate and long-term procedural and clinical outcomes.
Results: We isolated 882 of 844 PV (88.7%) after one procedure. Mean
age was 56.83±10.65 years and sex-ratio was 0.26 (54/207). 25 patients
(9.65%) presented with common left pulmonary vein trunk (CLPVT). In
73 patients (28.1%), an irrigated-tip radiofrequency (RF) catheter was used to
create a supplemental focal lesion. It was more frequently used for persistent
AF (p<0.001) and for CLPVT (p<0.001). Mean duration cryoballoon applica-
tion was 567 seconds (s) in left superior pulmonary vein (LSPV), 564 s in left
inferior pulmonary vein (LIPV), 531 s in right superior pulmonary vein
(RSPV) and 548 s in right inferior pulmonary vein (RIPV). Mean temperature
was –52° C in LSPV, –51° in LIPV, –50° in RSPV and –49° in RIPV. We
used a 28 mm balloon in 60.8% of cases, a 23 mm balloon in 19.6% and both
in 14.6%. The mean procedural duration was 143.55±38.8 min (70-275), and
fluoroscopic exposure 28.4±13.4 min (09-73). At the end of the procedure,
228 patients (87.7%) were in sinus rhythm. Over a mean period of
15.25±10 months (range of 3-38), 79.6% of patients had remained recurrence-
free with no significant difference between paroxysmal and persistent AF
(p=0.226), and also between CLPT and usual anatomy of PV (p=0.266).
23 patients had a second procedure. Phrenic nerve palsy was the most fre-
quent, though reversible complication.
Conclusions: PV isolation, using a cryoballoon, was completed with a
high rate of procedural and long-term success and low rate of complications.
Supplemented, when needed, by focal RF, cryoablation was a safe and effec-
tive alternative to a circumferential RF procedure.
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Aims: Coupled pacing (CP) which consists in an additional beat delivered
after the refractory period, has been proposed to reduce ventricular rate and
increase ventricular contractility. We hypothesized that CP may be added to
